VMD: Approved to delay the disclosure of Q2.2017 financial statements

On July 20, 2017, the State Securities Commission approved Vimedimex Medi – Pharma Joint Stock Company (VMD) to delay the disclosure of the financial statements, as follows:

-          The Company was allowed to release its Quarter 2.2017 financial statements and reviewed financial statements (if any) within 30 days from the last day of quarter, but no more than 05 days from the day when the audit firm signs the reviewed financial statements. 

HOSE

>   MVY: General Meeting of Shareholders Mandate 2017 (21/07/2017)

>   MCT: Financial Statement Quarter 2/2017 (21/07/2017)

>   HSG: Setting up three branches (21/07/2017)

>   SGR: Extraordinary AGM 2017 (21/07/2017)

>   FCS: Financial Statement Quarter 2/2017 (21/07/2017)

>   EIC: Financial Statement Quarter 2/2017 (21/07/2017)

>   DNH: Change Business Registration Certificate (21/07/2017)

>   DNS: Financial Statement Quarter 2/2017 (21/07/2017)

>   CTW: Financial Statement Quarter 2/2017 (holding company) (21/07/2017)

>   CMP: Financial Statement Quarter 2/2017 (21/07/2017)